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Schistosomiasisa b s t r a c t
Schistosomiasis, a snail-borne parasitic disease, affects more than 200 million people worldwide. Cur-
rently the treatment of schistosomiasis relies on a single therapy of praziquantel, a drug developed over
30 years ago. Thus, there is an urgent need to develop alternative antischistosomal drugs. In the pursuit of
novel antischistosomal drugs, we examined the antischistosomal activities of 45 compounds that had
been reported to exhibit antimicrobial and/or antiparasitic activities. Two plant-derived compounds,
plumbagin and sanguinarine, were found to possess potent antischistosomal activities in vitro. For both
the compounds, a concentration of 10 lM (equivalent to 1.88 lg/ml for plumbagin and 3.68 lg/ml for
sanguinarine) resulted in 100% mortality at 48 h, which meets the World Health Organization’s (WHO)
criterion of ‘‘hit’’ compounds for the control of schistosomiasis. Morphological changes and tegumental
alterations of the dead worms treated by the two compounds were quite different. The signiﬁcant mor-
phological changes of worms after treatment by the two compounds suggest the two compounds target
different biological pathways, both of which result in parasite’s death. This study provides evidence to
suggest plumbagin and sanguinarine have real potential as effective alternative chemotherapeutic agents
for the treatment of schistosomiasis.
 2012 Australian Society for Parasitology. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Schistosomiasis is a chronic, debilitating disease caused by
blood-dwelling trematodes of the genus Schistosoma. The global
health impact of schistosomiasis is second only to malaria. Accord-
ing to a recent World Health Organization (WHO) report, 239 mil-
lion people were infected with schistosomiasis (WHO, 2012). In
sub-Saharan Africa alone, an estimated 150,000 deaths per year
were attributable to schistosomiasis (van der Werf et al., 2003). In
addition, people infected with schistosomes may have increased
susceptibility to other infectious diseases such as HIV/AIDS (Secor,
2012). It resulted in up to 70 million disability-adjusted life years
(DALYs) lost annually. This number exceeds that of malaria and
tuberculosis, and nearly equivalent to the DALYs lost fromHIV/AIDS
(Hotez and Fenwick, 2009). Despite the impacts described, the
aggregate health impact of schistosomiasis is often underestimated
because of the complexity of evaluating the disease (King, 2010).
Considerable effort has been made in vaccine development,
which has been unsuccessful so far (McWilliam et al., 2012).Current treatment of schistosomiasis relies on the drug praziquan-
tel (PZQ), which was developed in the late 1970s (Seubert et al.,
1977). PZQ has been widely used as an effective means to control
schistosomiasis. However, PZQ does not treat early infection or
prevent reinfection (Magnussen, 2003). In addition, available evi-
dence indicates the emergence of PZQ resistance by schistosomes
(Cioli et al., 1993; Fallon and Doenhoff, 1994; Ismail et al., 1999).
For example, investigations in Egypt, Senegal and Kenya revealed
different degrees of PZQ drug resistance in Schistosoma mansoni (Is-
mail et al., 1999; Melman et al., 2009; van den Enden, 2009). More-
over, recent efforts to expand mass chemotherapy administrations
using PZQ (Webster et al., 2009) might accelerate the emergence of
drug resistance in schistosomes.
Some antiparasitic drugs like artemether and meﬂoquine, both
antimalarial drugs, as well as miltefosine, an antileishmanial drug,
have shown antischistosomal activity (Caffrey and Secor, 2011).
Administration of these drugs with or without PZQ is currently un-
der evaluation (Eissa et al., 2011; Keiser et al., 2011; Xiao et al.,
2011a). However, it is important to keep in mind the multi-use
of antimalarial drugs may put the control of malaria at risk. This
is likely due to the co-occurrence of schistosomes and malaria in
most endemic areas and also the well-documented ability of
Plasmodium to develop drug resistance. An older drug, oxamni-
quine, is no longer manufactured because it is only effective
against one species of schistosome, S. mansoni. Additionally, it
has been found to possess undesired side effects and promote drug
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such as the antioxidant inhibitors, oxadiazoles (Sayed et al., 2008),
and some protease inhibitors (Abdulla et al., 2007) have promising
potentials against a schistosome infection, but have yet to reach
clinical trials. Developing drugs for neglected tropical diseases is
largely ignored; i.e., out of 1599 new drugs developed worldwide
from 1975 to 2004, only 21 were for patients with neglected trop-
ical diseases (Renslo and McKerrow, 2006) despite the large num-
bers of infected individuals worldwide. Developing a new drug in
general is very complicated, only one in ten drug projects at the
discovery phase progress to clinical development (Brown and
Superti-Furga, 2003). Thus to alleviate these challenges, efforts to
explore and discover novel ‘‘hit’’ and ‘‘lead’’ chemotherapeutic
compounds are continually undertaken.
In the search of new candidates of alternative antischistosomal
drugs, we tested the antischistosomal activities of 45 compounds
that had been reported to possess antiparasitic and/or antimicro-
bial activities. We found that two plant-derived compounds,
plumbagin and sanguinarine, possess potent antischistosomal
activities. In this paper we describe the antischistosomal activities
of the two compounds as well as the morphological changes and
tegumental changes observed in the worms after treatment with
the two compounds.
2. Materials and methods
2.1. Parasites
NIH strain S. mansoni (NIH-SM-PR2) was maintained in the lab-
oratory using the M line snail Biomphalaria glabrata and mice as
intermediate and deﬁnitive hosts, respectively (Zhang and Coultas,
2011). All procedures of schistosome infection and mouse perfu-
sion were conducted in accordance with protocols approved by
the University of New Mexico Institutional Animal Care and Use
Committee.
2.2. Compounds
If not otherwise stated, all chemical reagents were purchased
from Sigma (http://www.sigmaaldrich.com/united-states.html)
and are listed below. The number in parenthesis is the catalogue
number of the product: albendazole (A4673), amodiaquin dihydro-
chloride dehydrate (A2799), anacardic acids (A7236), apicidin
(A8851), arachidonic acid (A9673), artemether (A9361), atovaqu-
one (A7986), berberine chloride hydrate (14050), bisdemethoxy-
curcumin (B6938), chelidonine (54274), chloroquine diphosphate
salt (C6628), closantel (34093), curcumin (C1386), diclofenac so-
dium salt (D6899), dipyridamole hydrochloride (D9766), docosa-
hexaenoic acid (D2534), doxycycline hyclate (D9891), ethacrynic
acid, etazolate hydrochloride (E1896), halofantrine hydrochloride
(H9414), humic acid (53680), 2-hydroxy-1,4-naphthoquinone
(H46805), ibuprofen (I4883), lapachol (I2905), levamisol hydro-
chloride (31742), macrocyclic lactone (437026), mebendazole
(M2523), meﬂoquine hydrochloride (M2319), methylene blue
(M9140), metronidazole (M3761), miltefosine (M5571),
2-methoxy-1,4-naphthoquinone (189162), 1,2-naphthoquinone
(346616), oxantel pamoate (O4755), oxfendazole (34176), prazi-
quantel (P4668), pyrantel pamoate (P6210), piperazine (80621),
plumbagin (P7262), pyrimethamine (46706), primaquine bisphos-
phate (160393), quine (22620), sanguinarine (S5890), sulfadoxine
(S7821), sulfadiazine (S8626), and trichostatin A (T8552).
2.3. Culture of schistosome worms with compounds
All adult schistosome worms were collected from mice after
42–45 days post exposure to S. mansoni. Stock solutions of individ-ual chemical reagents were prepared in dimethylsufoxide (DMSO)
(EMD Chemicals) and stored in 30 C. The ﬁnal concentration of
DMSO in all treatments, including control, was 1% (v/v). The en-
riched RPMI (eRPMI) 1640 culture medium contained 25 mM
HEPES, 10% fetal bovine serum (FBS), 125 units/ml each penicillin
and streptomycin (all from Gibco) (Coultas and Zhang, 2012). The
worms were washed with eRPMI three times and placed into a
6-well plate. In each well, 20–50 worms were cultured in 5 ml cul-
ture medium. For the control, the worms were treated with equal
amounts of DMSO alone. The worms were cultured at 37 C in an
atmosphere of 5% CO2. The criterion for classifying dead worms
was made according to Eissa et al. (2011) and Manneck et al.
(2010) with a more stringent modiﬁcation as described below.
The plate was agitated slightly to ensure better parasitic visibility
and then placed under a stereomicroscope. Worms that did not ex-
hibit motility, particularly in the mouth region, for two minutes
were considered dead.
The measurement of length of worms was conducted under a
Zeiss Axioskop 2 Plus Mot Plus microscope. A high-resolution
microscopy camera, AxioCam HRc, was used to photograph the
worms. After photography, the curve line in the middle of worm
body was drawn to represent the actual length of the worm and
exact length of the worm was calculated by a computer connected
to the microscope.
With regard to effect of compounds on mortality of cercariae,
50–120 cercariae were placed into a 24-well plate. For a given
compound, triplicates at each concentration were performed. Live
cercariae show very active movement, thus if no movement was
observed, cercariae exhibiting no movement for one minute were
considered dead under the Zeiss stereo microscope (Discovery
V8). In addition, the death of cercariae as described above was also
veriﬁed by the propidium iodide staining method (Coultas and
Zhang, 2012).
2.4. Scanning electron microscopy (SEM) study
After the adult worms were incubated in the medium that con-
tained either compounds to be tested or a DMSO control, worm
samples were collected and washed with fresh eRPMI two times.
Worm samples were then washed two more times with phosphate
buffer saline (PBS) for 10 min. each at room temperature (RT) to re-
move any residual compounds and/or media before ﬁxing. Next,
samples were ﬁxed in 2.5% glutaraldehyde in PBS buffer (0.1 mol/
L, pH 7.4) overnight at 4 C. After ﬁxing for 24 h, samples were
washed with PBS four times for 10 min. each at RT. Samples were
dehydrated in a series of ethanol washes (25%, 50%, 70%, 75%, 85%,
95% and 100% ethanol) for 10 min each at room temperature. The
100% ethanol wash was performed two times. Samples were criti-
cally point dried, mounted on carbon paste and coated with gold/
palladium before examining with the JEOL 5800LV scanning elec-
tron microscope.
3. Results
3.1. Plumbagin and sanguinarine exhibit potent antischistosomal
activities in vitro
The compounds that resulted in 100% mortality at a concentra-
tion of 50 lM after four days were further investigated. Among the
45 compounds tested (as listed in the Section 2), six compounds
(PZQ, plumbagin, sanguinarine, curcumin, meﬂoquine and miltefo-
sine) met the criterion and received further investigation.
Among the six compounds depicted in Fig. 1, the antischistoso-
mal activity of PZQ was the most effective. In addition, the efﬁcacy
of plumbagin and sanguinarine were better than that of curcumin,
meﬂoquine or miltefosine.
Fig. 1. In vitro antischistosomal activities. Effect of compounds at various concen-
trations on the mortality of schistosome worms under culture conditions. The data
was generated from three independent studies and the time (day) of death was
determined based on two or three consistent experiments. No obvious mortality in
control groups (DMSO) was observed within 4 days of worm culture or 4 h of
cercariae culture. The ﬁnal concentration of DMSO is 1% (v/v) for all experiments.
Note that the intervals on the X-axis are not equal.
Fig. 2. Effect of various concentrations of plumbagin and sanguinarine on the
survival of worms. The average percent of live worms is shown. The average
percentages were generated from three independent experiments and the bars
show the range of live worm percentages in the experiments. Note that the
intervals on the X-axis are not equal.
Fig. 3. Effect of compounds on the survival of cercariae. (A) The effect of various
concentrations of compounds on cercariae mortality. The data was generated from
three independent studies and the time (hour) of death was determined based on
two or three consistent experiments. Note that the intervals on the X-axis are not
equal. (B) Upper (a) and lower (b) images showing cercariae after treatment with
plumbagin and sanguinarine, respectively.
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meﬂoquine and miltefosine compared to plumbagin and sanguin-
arine, as well as the data published for the antischistosomal activ-
ity of the compounds, we focused in the subsequent studies on the
effect of different concentrations of plumbagin and sanguinarine
on the mortality of the worms (Fig. 2). Investigation revealed that
all worms were killed by either of the two compounds within 6 h at
50 lM. At a concentration of 30 lM, the time required for 100%
mortality for sanguinarine and plumbagin we found to be 6 and
12 h respectively. At a concentration of 10 and 5 lM, the time to
reach full mortality for sanguinarine was 24 and 72 h, respectively
and the time to reach full mortality for plumbagin at these concen-
trations was 48 and 96 h, respectively. Taken together, this study
demonstrates that both compounds possess potent antischistoso-
mal effects and that sanguinarine is more effective against adult
worms than plumbagin.
Finally, we compared the effects of plumbagin and sanguinarine
and other compounds described in Fig. 1 on the killing of cercariae
(Fig. 3A). Our study indicated that cercariae are much more sensi-
tive to the chemicals than adult worms. Similarly, the efﬁcacies ofthe compounds tested on killing cercariae were somewhat consis-
tent with those of the worm experiments described above. We
found that sanguinarine displayed the strongest anticercariae ef-
fect amongst the compounds investigated. Notable still, plumbagin
possessed similar schistosomicidal effects to that of PZQ. More-
over, we found the plumbagin caused a high percentage of separa-
tion of cercariae heads from tails whereas sanguinarine resulted in
fewer separations. While plumbagin caused muscle contractions,
which lead to the splitting of the head from the tail, sanguinarine
seemed to simply paralyze the cercariae (Fig. 3B).3.2. Plumbagin leads to worm contraction, but sanguinarine does not
In addition to the profound in vitro schistosomicidal effects de-
scribed above, we also noted that the morphological appearance of
the dead adult worms treated by the two compounds was quite
different (Fig. 4). Adult worms treated with plumbagin became
contracted, immobile and at times, appeared tightly coiled. The
length of dead male and female worms after treatment with
plumbagin was respectively about 54% and 70% of the length of
worms incubated with DMSO (P < 0.01). Conversely, no such mor-
phological changes were observed in the sanguinarine-treated
worms in both sexes, as compared to the control group (Fig. 4A
and B).3.3. Both compounds can cause tegumental alterations, but each
compound exhibits different effects on the tegument
To better understand the effects of the compounds on the worm
tegument, the interface between host and parasite, we used SEM to
examine the surface membrane of worms under different treat-
ments. We found that both compounds signiﬁcantly damaged the
worm’s tegument (Fig. 5). Interestingly, in most cases, plumbagin
showed prominent alterations of the tegumental surfaces, usually
with disintegration of tubercles and often times accompanied by
a decrease in the number of spines. Emergence of holes on the sur-
face was also observed (Fig. 5C and D). Sanguinarine treatment re-
sulted in severe erosion and disintegration of the tegumental
surface between tubercles, however the tubercles and spines were
relatively intact. In fact, some tubercles did not display spine loss
while other tubercles simply had fewer spines (Fig. 5E and F). For
both compounds, the tegument of female worms after treatment
are shown to varying degrees of swelling and cracking ranging
Fig. 4. Comparison of morphological differences of the dead worms after treatment
with plumbagin (PBG) and sanguinarine (SGR). (A) Morphological appearance of
dead schistosome worms after treatment with sanguinarine (left) and plumbagin
(right) (under a microscopic ﬁeld). (B) Actual average size of dead worms (male and
female) after treatment with either sanguinarine, plumbagin or DMSO (control). No
signiﬁcant difference was found between sanguinarine and DMSO control in either
sex.
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tegumental ridges/ﬁssures.
4. Discussion
In this study, 45 compounds that had been reported to possess
antiparasitic and/or antimicrobial activities were selected for our
antischistosomal experiments. Among them, six compounds
(plumbagin, sanguinarine, PZQ, curcumin, meﬂoquine and miltefo-
sine) were found to possess schistosomicidal activity based on the
criterion of our experiment (e.g., 100% mortality at a concentration
of 50 lM for four days). The antischistosomal activity of PZQ was
the most profound amongst all compounds tested and the efﬁcacy
of the two compounds identiﬁed (plumbagin and sanguinarine)
were better than that of curcumin, meﬂoquine and miltefosine,
the three compounds known to possess schistosomicidal activity.
Curcumin, a plant-derived compound, has been recently studied
as a potential antischistosomal drug (Allam, 2009; Magalhães
et al., 2009; Luz et al., 2012). The antimalarial drug, meﬂoquine,
(Keiser et al., 2011; Xiao et al., 2011b) and the antileishmanial
drug, miltefosine (Eissa et al., 2011) have also recently been tested
as alternative drugs for schistosomiasis based on animal models or
small clinic trails. Thus our comparative study suggests plumbagin
and sanguinarine have signiﬁcant potentials as novel antischistos-
omal chemotherapeutics.
Although we did not observe discernible antischistosomal activ-
ity in many agents (listed in the Section 2, but not shown in Fig. 1),
it does not necessarily mean those compounds do not have such an
effect. For example, artemether has been reported to possess anantischistosomal effect (Abdul-Ghani et al., 2011; Xiao et al.,
2011a). Others, such as pyrantel pamoate, oxantel pamoate, levam-
isol, mebendazole, albendazole, oxfendazole, metronidazole and
piperazine, have also been reported to possess certain levels of
anthelmintic effects, particularly in antinematode responses (Mar-
tin and Robertson, 2010; Beech et al., 2011; Müllner et al., 2011;
van den Enden, 2009), but they showed very limited antischistos-
omal activities in our in vitro comparative study. The reason we did
not ﬁnd apparent antischistosomal effects in our experiments for
these compounds may be due to our use of relatively low concen-
trations of the chemicals, which might have reduced the chance of
observing antischistosomal activity. Another plausible explanation
for why we did not observe antischistosomal effects for the com-
pounds that others did, especially in nematodes, may be due to a
high phylogenetic divergence between nematodes and trematodes.
Nematodes and trematodes belong to the two superphyla of pro-
tostomes, Ecdysozoa and Lophotrochozoa, respectively. It is pre-
dicted that molecular structure of drug-related receptors and
relevant pathways are quite different, which will affect the efﬁ-
ciency of a given drug. Nevertheless, our study suggests that
plumbagin and sanguinarine have better efﬁcacy against schistoso-
miasis than all the other compounds tested in our investigation.
Our study shows that a concentration of 10 lM (equivalent to
1.88 lg/ml for plumbagin and 3.68 lg/ml for sanguinarine) of both
compounds resulted 100% mortality at 48 h. WHO’s deﬁnition and
activity criteria for hits and leads sets inhibition of 100% motility of
adult worms at a concentration of 5 lg/ml (in vitro) and 80% worm
reduction after ﬁve injections at a dosage 100 mg/kg body-weight/
day (in vivo) (Hwaka and Hudson, 2006). Clearly, plumbagin and
sanguinarine meet WHO’s criterion for ‘‘hit’’ compounds and are
effective against schistosomes. Moreover, our comparative studies
revealed that the in vitro antischistosomal effects of the two com-
pounds is better than other antischistosomal drugs such as arteme-
ther, meﬂoquine, miltefosine and curcumin that are under current
investigation as alternative therapies (Allam, 2009; Sissoko et al.,
2009; Eissa et al., 2011; Keiser et al., 2011; Xiao et al., 2011a,b;
Luz et al., 2012). These exciting ﬁndings provide a strong impetus
to investigate the in vivo efﬁcacy of plumbagin and sanguinarine on
schistosomes in the future.
In addition to the antischistosomal activity described, it is
intriguing that the morphological appearance of the dead worms
after treatment with plumbagin and sanguinarine is quite differ-
ent. Worms treated with plumbagin become withered while
worms treated with sanguinarine show no apparent changes in
appearance after death. It seems that plumbagin causes muscle
contraction, but sanguinarine does not. This change is similarly ob-
served in experiments of cercariae, where muscle contraction
caused by plumbagin may be responsible for the high rate of head
separation observed (Fig. 3B). Taken together, these differences im-
ply there are at least two different mechanisms involved in the
parasite’s death. Based on the observations, it seems that plumba-
gin affects muscle function because of the muscle contraction ob-
served. In the case of sanguinarine, it paralyzes the worms,
potentially through the nervous system. Due to the complexity of
drug mechanisms and their mode of action, comparative investiga-
tion of these differences using molecular approaches may reveal
the fundamental mechanism(s) of killing the parasites, which in
turn, can facilitate the design of new drugs to combat
schistosomiasis.
Another intriguing phenomenon we observed is that plumbagin
and sanguinarine, although possessing different effects on schisto-
somes, can both alter the tegumental structure of the worms; i.e.,
both compounds damage the tegument, thus implying their antis-
chistosomal effect may increase in the host. This is due to the fact
that the tegument is the interface between the host and parasite
and harbors large amounts of molecules that constitute very com-
Fig. 5. SEM images showing teguments of male (left panel) and female worms (right panel) after culture with DMSO (A, B), plumbagin (C, D) and sanguinarine (E, F). (A) and
(B) show SEM image of the normal tegument of male and female worms. Male teguments shows hill-shaped tubercles covered with pointed spines and a convoluted surface
of the tegumental membrane between tubercles. The female tegument does not have tubercles and spines and appears like a ﬁeld plowed surface. (C) Shows a SEM image of a
male worm exposed in vitro to plumbagin at a concentration of 10 lM for 24 h. Tegumental surfaces are damaged usually with disintegration of tubercles accompanied by a
decrease in the number of spines. In addition, there were varying degrees of disintegration of the tegumental surfaces including peeling, wrinking and blebbing. (D) Among
the female worms treated with plumbagin at a concentration of 10 lM for 24 h, the worms displayed moderate damage when compared to male damage of the tegumental
surface. Holes and divots are prevalent throughout the tegument. (E) SEM image shows the tegument of an adult worm exposed in vitro to sanguinarine at a concentration of
10 lM for 24 h. Distortions of the tegumental surfaces can be seen usually with severe erosion and disintegration of the tegumental surface between tubercles. The holes and
broken surface are visible. (F) Female worms treated with 30 lM sanguinarine for 8 h displayed varying degrees of swelling and cracking ranging from minimal to moderate
throughout the anterior and posterior tegumental ridges/ﬁssures.
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membrane and tegumental integrity play a vital role in immune
evasion, modulation and nutrient uptake and thus ensure worm
survival in the host. Profound damage caused by the two
compounds observed here could alter tegumental structure andstability. In addition to the direct effect on the survival of the
worms, tegumental alteration might result in exposing the typi-
cally unexposed parasite antigens to the host’s immune system.
As a result, treatment with plumbagin and sanguinarine might
increase the vulnerability of parasites in the host and thus further
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in vivo.
Plumbagin and sanguinarine are plant-derived products (Reuter
et al., 2011). Exploring natural products has long been considered
an ideal alternative for the development of new drugs (Geary
et al., 2012). According to data of all approved agents from 1981
to 2006, about 50% of new drugs were directly or indirectly derived
from natural products (Newman and Cragg, 2007). With respect to
parasitic diseases, many compounds isolated from plants have pro-
ven to be the mainstay in anthelmintics and antimalarial therapy.
For example, there are notable plant-derived antiparasitic drugs
such as quinolone alkaloids against Leishmania amazonensis and in-
dole alkaloids against Plasmodium and Entamoeba (Kayser et al.,
2003). Three major antimalarial drugs, chloroquine, atovaquone
and artemisinin, are derived from plants (Oliveira et al., 2009).
Chloroquine was synthesized based on the structure of quinine, a
component of the tree bark Cinchona spp. that was used to treat
malaria 400 years ago (Achan et al., 2011). Atovaquone was struc-
turally derived from lapachol, originally puriﬁed from Tabebuia
spp. Artemisinin was extracted from Artemisia annua and many
more effective drugs such as artemether were designed based on
the artemisinin (Miller and Su, 2011). In light of these discoveries,
similar efforts on schistosomiasis should be emphasized (Ribeiro-
dos-Santos et al., 2006). Although a few plant products have been
screened for activity against schistosomes (Cichewicz et al., 2002;
Sanderson et al., 2002; Allam, 2009; Magalhães et al., 2010), pres-
ently no antischistosomal compounds have been puriﬁed and
reported.
Plumbagin is one of the simplest secondary plant metabolites of
the three major families, Plumbaginaceae, Droseraceae and Ebena-
ceae. It exhibits many highly potent biological activities including
activation of apoptosis, induction of redox cycling and modiﬁcation
of chromatin structure. Plumbagin and its derivatives can act as an
antioxidant, anti-inﬂammatory, anticancer, antibacterial and anti-
fungal agents (Padhye et al., 2012). Additionally, plumbagin is
capable of inhibiting the drug efﬂux mechanism in drug-resistant
bacteria, thereby allowing intracellular accumulation of potent
drug molecules. With regard to an antiparasitic role, evidence
showed that plumbagin possesses antiﬁlarial activity by inhibiting
trypanothione and glutathione S-transferases (Srinivasan et al.,
2009; Sharma et al., 2012).
During the process of submission of our manuscript, we noted
that a paper describing the antischistosomal role of plumbagin
was published (Lorsuwannarat et al., 2012). Although the effect
of plumbagin on mortality of larvae (cercariae) and the morphol-
ogy of adult worms was not described in the paper, the published
paper and ours provide independent evidence supporting an antis-
chistosomal role of plumbagin on adult worms. The slight differ-
ences observed between the two reports in terms of efﬁcacy
in vitro and tegumental changes may be due to the different strains
of S. mansoni used in each investigation.
Sanguinarine is derived from the root of Sanguinaria spp and
possesses a wide spectrum of biological assets including antimicro-
bial, antioxidant and anti-inﬂammatory properties. Sanguinarine
can induce apoptosis in malignant cell types and interact with
chromatin and modulate it epigenetically (Selvi et al., 2009). Active
efforts have been made to develop sanguinarine and its derivatives
as anticancer agents (Sun et al., 2010; Pica et al., 2012). A recent
study has also revealed sanguinarine’s role in killing the ﬁsh para-
site Ichthyophthirius multiﬁliis (Yao et al., 2010). Our data presented
here provides the ﬁrst evidence suggesting an antischistosomal
role of sanguinarine.
Previous studies have shown that plumbagin and sanguina-
rine have a wide array of medical and health applications,
hence it would not be surprising if they additionally possesspotent antischistosomal activities. Both compounds belong to
naphthoquinones, a large family of chemical compounds. A re-
cent study suggested that a slight modiﬁcation of some napth-
thoquinone compounds could increase antileishmanial activity
(Ali et al., 2011). This might imply that the compounds, if de-
signed properly, may be an effective antischistosomal therapy.
In fact, we have already conﬁrmed that some analogs of the
two compounds have a similar antischistosomal activity (data
not shown), implying the two chemicals identiﬁed in this study
can serve as basic compounds for development of novel chemo-
therapeutics to control schistosomiasis in the future. Given the
broad spectrum of documented pharmacological activities
exhibited by the compounds, they continue to be the subject
of extensive studies to evaluate possible therapeutic applica-
tions in human health. This will make future development of
the two compounds as antischistosomal therapy relatively easy.References
Abdul-Ghani, R., Loutfy, N., Sheta, M., Hassan, A., 2011. Artemether shows
promising female schistosomicidal and ovicidal effects on the Egyptian strain
of Schistosoma mansoni after maturity of infection. Parasitol. Res. 108, 1199–
1205.
Abdulla, M.H., Lim, K.C., Sajid, M., McKerrow, J.H., Caffrey, C.R., 2007. Schistosomiasis
mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med. 4,
e14.
Achan, J., Talisuna, A.O., Erhart, A., Yeka, A., Tibenderana, J.K., Baliraine, F.N.,
Rosenthal, P.J., D’Alessandro, U., 2011. Quinine, an old anti-malarial drug in a
modern world: role in the treatment of malaria. Malar. J. 10, 144.
Ali, A., Assimopoulou, A.N., Papageorgiou, V.P., Kolodziej, H., 2011. Structure/
antileishmanial activity relationship study of naphthoquinones and
dependency of the mode of action on the substitution patterns. Planta Med.
77, 2003–2012.
Allam, G., 2009. Immunomodulatory effects of curcumin treatment on murine
Schistosomiasis mansoni. Immunobiology 214, 712–727.
Beech, R.N., Skuce, P., Bartley, D.J., Martin, R.J., Prichard, R.K., Gilleard, J.S., 2011.
Anthelmintic resistance: markers for resistance, or susceptibility? Parasitology
138, 160–174.
Brown, D., Superti-Furga, G., 2003. Rediscovering the sweet spot in drug discovery.
Drug Discov. Today 8, 106–1077.
Caffrey, C.R., Secor, W.E., 2011. Schistosomiasis: from drug deployment to drug
development. Curr. Opin. Infect. Dis. 24, 410–417.
Cichewicz, R.H., Lim, K.V., McKerrow, J.H., Nair, M.G., 2002. Kwanzoquinones A-G
and other constituents of Hemerocallis fulva ‘Kwanzo’ roots and their activity
against the human pathogenic trematode Schistosoma mansoni. Tetrahedron 58,
8597–8606.
Cioli, D., Pica-Mattoccia, L., Archer, S., 1993. Drug resistance in schistosomes.
Parasitol. Today 9, 162–166.
Coultas, K.A., Zhang, S.-M., 2012. In vitro cercariae transformation: comparison of
mechanical and nonmechanical methods and observation of morphological
changes of detached cercariae tails. J. Parasitol.. http://dx.doi.org/10.1645/GE-
30721.1.
Eissa, M.M., El-Azzouni, M.Z., Amer, E.I., Baddour, N.M., 2011. Miltefosine, a
promising novel agent for Schistosomiasis mansoni. Int. J. Parasitol. 41, 235–242.
Fallon, P.G., Doenhoff, M.J., 1994. Drug-resistant schistosomiasis: resistance to
praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug
speciﬁc. Am. J. Trop. Med. Hyg. 51, 83–88.
Geary, T.G., Chibale, K., Abegaz, B., Andrae-Marobela, K., Ubalijoro, E., 2012. A new
approach for anthelmintic discovery for human. Trends Parasitol. 28, 176–181.
Hotez, P.J., Fenwick, A., 2009. Schistosomiasis in Africa: an emerging tragedy in our
new global health decade. PLoS Negl. Trop. Dis. 3, e485.
Hwaka, S., Hudson, A., 2006. Innovative lead discovery strategies for tropical
diseases. Nat. Rev. Drug Discov. 5, 941–955.
Ismail, M., Botros, S., Metwally, A., William, S., Farghally, A., Tao, L.F., Day, T.A.,
Bennett, J.L., 1999. Resistance to praziquantel: direct evidence from Schistosoma
mansoni isolated from Egyptian villagers. Am. J. Trop. Med. Hyg. 60, 932–935.
Kayser, O., Olbrich, C., Croft, S.L., Kiderlen, A.F., 2003. Formulation and
biopharmaceutical issues in the development of drug delivery systems for
antiparasitic drugs. Parasitol. Res. 2, S63–S70.
Keiser, J., Manneck, T., Vargas, M., 2011. Interactions of meﬂoquine with
praziquantel in the Schistosoma mansoni mouse model and in vitro. J.
Antimicrob. Chemother. 66, 1791–1797.
King, C.H., 2010. Parasites and poverty: the case of schistosomiasis. Acta Trop. 113,
95–104.
Lorsuwannarat, N., Saowakon, N., Ramasoota, P., Wanichanon, C., Sobhon, P., 2012.
The anthelmintic effect of plumbagin on Schistosoma mansoni. Exp. Parasitol..
http://dx.doi.org/10.1016/j.exppara.2012.10.003.
34 S.-M. Zhang, K.A. Coultas / International Journal for Parasitology: Drugs and Drug Resistance 3 (2013) 28–34Luz, P.P., Magalhães, L.G., Pereira, A.C., Cunha, W.R., Rodrigues, V., Andrade, E., Silva,
M.L., 2012. Curcumin-loaded into PLGA nanoparticles: preparation and in vitro
schistosomicidal activity. Parasitol. Res. 110, 593–598.
Magalhães, L.G., Machado, C.B., Morais, E.R., Moreira, E.B., Soares, C.S., da Silva, S.H.,
da Silva Filho, A.A., Rodrigues, V., 2009. In vitro schistosomicidal activity of
curcumin against Schistosoma mansoni adult worms. Parasitol. Res. 104, 1197–
1201.
Magalhães, L.G., Kapadia, G.J., da Silva Tonuci, L.R., Caixeta, S.C., Parreira, N.A.,
Rodrigues, V., da Silva Filho, A.A., 2010. In vitro schistosomicidal effects of some
phloroglucinol derivatives from Dryopteris species against Schistosoma mansoni
adult worms. Parasitol. Res. 106, 395–401.
Magnussen, P., 2003. Treatment and re-treatment strategies for schistosomiasis
control in different epidemiological settings: a review of 10 years’ experiences.
Acta Trop. 86, 243–254.
Manneck, T., Haggenmüller, Y., Keiser, J., 2010. Morphological effects and
tegumental alterations induced by meﬂoquine on schistosomula and adult
ﬂukes of Schistosoma mansoni. Parasitology 137, 85–98.
Martin, R.J., Robertson, A.P., 2010. Control of nematode parasites with agents acting
on neuro-musculature systems: lessons for neuropeptide ligand discovery. Adv.
Exp. Med. Biol. 692, 138–154.
McWilliam, H.E., Driguez, P., Piedraﬁta, D., McManus, D.P., Meeusen, E.N., 2012.
Novel immunomic technologies for schistosome vaccine development. Parasite
Immunol. 34, 276–284.
Melman, S.D., Steinauer, M.L., Cunningham, C., Kubatko, L.S., Mwangi, I.N., Wynn,
N.B., Mutuku, M.W., Karanja, D.M., Colley, D.G., Black, C.L., Secor, W.E., Mkoji,
G.M., Loker, E.S., 2009. Reduced susceptibility to praziquantel among naturally
occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl. Trop. Dis. 3, e504.
Miller, L.H., Su, X., 2011. Artemisinin: discovery from the Chinese herbal garden.
Cell Host Microbe 6, 855–858.
Müllner, A., Helfer, A., Kotlyar, D., Oswald, J., Efferth, T., 2011. Chemistry and
pharmacology of neglected helminthic diseases. Curr. Med. Chem. 18, 767–789.
Newman, D.J., Cragg, G.M., 2007. Natural products as sources of new drugs over the
last 25 years. J. Nat. Prod. 70, 461–477.
Oliveira, A.B., Dolabela, M.F., Braga, F.C., Jácome, R.L., Varotti, F.P., Póvoa, M.M., 2009.
Plant-derived antimalarial agents: new leads and efﬁcient phythomedicines.
Part I. Alkaloids. An. Acad. Bras. Cienc. 81, 715–740.
Padhye, S., Dandawate, P., Yusuﬁ, M., Ahmad, A., Sarkar, F.H., 2012. Perspective on
medicine properties of plumbagin and its analogs. Med. Res. Rev. 32, 1131–
1158.
Pica, F., Balestrieri, E., Seraﬁno, A., Sorrentino, R., Gaziano, R., Moroni, G., Moroni, N.,
Palmieri, G., Mattei, M., Garaci, E., Sinibaldi-Vallebona, P., 2012. Antitumor
effects of the benzophenanthridine alkaloid sanguinarine in a rat syngeneic
model of colorectal cancer. Anticancer Drugs 23, 32–42.
Renslo, A.R., McKerrow, J.U., 2006. Drug discovery and development for neglected
parasitic diseases. Nat. Chem. Biol. 2, 701–710.
Reuter, S., Gupta, S.C., Park, B., Goel, A., Aggarwal, B.B., 2011. Epigenetic changes
induced by curcumin and other natural compounds. Genes Nutr. 6, 93–108.
Ribeiro-dos-Santos, G., Verjovski-Almeida, S., Leite, L.C., 2006. Schistosomiasis – a
century searching for chemotherapeutic drugs. Parasitol. Res. 99, 505–521.
Sanderson, L., Bartlett, A., Whitﬁeld, P.J., 2002. In vitro and in vivo studies on the
bioactivity of a ginger (Zingiber ofﬁcinale) extract towards adult schistosomes
and their egg production. J. Helminthol. 76, 241–247.Sayed, A.A., Simeonov, A., Thomas, C.J., Inglese, J., Austin, C.P., Williams, D.L., 2008.
Identiﬁcation of oxadiazoles as new drug leads for the control of
schistosomiasis. Nat. Med. 14, 407–412.
Secor, W.E., 2012. The effects of schistosomiasis on HIV/AIDS infection, progression
and transmission. Curr. Opin. HIV AIDS 7, 254–259.
Selvi, B.R., Pradhan, S.K., Shandilya, J., Das, C., Sailaja, B.S., Shankar, G.N., Gadad, S.S.,
Reddy, A., Dasgupta, D., Kundu, T.K., 2009. Sanguinarine interacts with
chromatin, modulates epigenetic modiﬁcations, and transcription in the
context of chromatin. Chem. Biol. 16, 203–216.
Seubert, J., Pohlke, R., Loebich, F., 1977. Synthesis and properties of Praziquantel, a
novel broad spectrum anthelmintic with excellent activity against
Schistosomes and Cestodes. Experientia 33, 1036–1037.
Sharma, N., Shukla, A.K., Das, M., Dubey, V.K., 2012. Evaluation of plumbagin and its
derivative as potential modulators of redox thiol metabolism of Leishmania
parasite. Parasitol. Res. 110, 341–348.
Sissoko, M.S., Dabo, A., Traore, H., Diallo, M., Traore, B., Konate, D., Niare, B., Diakite,
M., Kamate, B., Traore, A., Bathily, B., Tapily, A., Toure, O.B., Cauwenbergh, S.,
Jansen, H.F., Doumbo, O.K., 2009. Efﬁcacy of artesunate +
sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of
Schistosoma haematobium in children. PLoS One, e6732.
Srinivasan, L., Mathew, N., Muthuswamy, K., 2009. In vitro antﬁlarial activity of
glutathione S-transferase inhibitors. Parasitol. Res. 105, 1179–1183.
Sun, M., Lou, W., Chun, J.Y., Cho, D.S., Nadiminty, N., Evans, C.P., Chen, J., Yue, J.,
Zhou, Q., Gao, A.C., 2010. Sanguinarine suppresses prostate tumor growth and
inhibits survivin expression. Genes Cancer 1, 283–292.
van den Enden, E., 2009. Pharmacotherapy of helminth infection. Expert Opin
Pharmacother. 10, 435–451.
van der Werf, M.J., de Vlas, S.J., Brooker, S., Looman, C.W., Nagelkerke, N.J., Habbema,
J.D., Engels, D., 2003. Quantiﬁcation of clinical morbidity associated with
schistosome infection in sub-Saharan Africa. Acta Trop. 86, 125–139.
Webster, J.P., Koukounari, A., Lamberton, P.H., Stothard, J.R., Fenwick, A., 2009.
Evaluation and application of potential schistosome-associated morbidity
markers within large-scale mass chemotherapy programmes. Parasitology
136, 1789–1799.
WHO, 2012. Accelerating work to overcome the global impact of neglected tropical
disease: a roadmap for implementation. <http://www.who.int/neglected_
diseases/NTD_RoadMap_2012_Fullversion.pdf>.
Xiao, S.H., Mei, J.Y., Jiao, P.Y., 2011a. Effect of meﬂoquine administered orally at
single, multiple, or combined with artemether, artesunate, or praziquantel in
treatment of mice infected with Schistosoma japonicum. Parasitol. Res. 108,
399–406.
Xiao, S.H., Xue, J., Zhang, H.B., 2011b. Further studies on meﬂoquine and
praziquantel alone or interaction of both drugs against Schistosoma japonicum
in vitro. Parasitol. Res. 110, 1239–1248.
Yao, J.Y., Shen, J.Y., Li, X.L., Xu, Y., Hao, G.J., Pan, X.Y., Wang, G.X., 2010. Effect of
sanguinarine from the leaves of Macleaya cordata against Ichthyophthirius
multiﬁliis in grass carp (Ctenopharyngodon idella). Parasitol. Res. 107, 1035–
1042.
Zhang, S.-M., Coultas, K.A., 2011. Identiﬁcation and characterization of ﬁve
transcription factors that are associated with evolutionarily conserved
immune signaling pathways in the schistosome-transmitting snail
Biomphalaria glabrata. Mol. Immunol. 48, 1868–1881.
